Resminostat maintenance for advanced cutaneous lymphoma: RESMAIN study

Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses the RESMAIN study (NCT02953301), investigating resminostat as a maintenance therapy for advanced mycosis fungoides or Sézary syndrome. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

• categorie